News, features, and commentary about cancer-related issues ...

Niraparib and abiraterone acetate regimen demonstrates clinically meaningful delay in disease progression, nearly halving the risk of progression or death, with an early trend toward improved overall ...

Metastatic prostate cancer is currently associated with high morbidity and mortality rates. In addition, patients respond very differently to standard treatments such as hormone therapy or radiation ...

Manufacturing optimization is projected to expand batch output by ~50%, improving supply reliability and supporting higher-throughput PSMA PET imaging services. Increased radioactivity extends shelf ...

In welcome good news, Telix says the first stage of its pivotal prostate cancer therapeutic trial has hit its desired safety ... Read More The post Health Check: Telix jumps first hurdle with its ...

FDA approved Pylarify TruVu, a higher-radioactivity-concentration formulation of piflufolastat F 18 designed to increase batch size and distribution efficiency while maintaining the established ...

Prostate cancer is the most common cancer in men throughout the United States. Most men do not realize they have cancer due ...

Docetaxel added to androgen deprivation therapy (ADT) was the most cost-effective first-line regimen for patients with ...

It’s important to follow guidance on prostate-specific antigen screening that maximizes benefits and minimizes potential harms such as overdiagnosis and overtreatment.

The U.S. Food and Drug Administration on Friday approved a new formulation of Lantheus Holdings' prostate cancer imaging ...

Investing.com-- Shares of Telix Pharmaceuticals (ASX:TLX) jumped on Tuesday after the company reported positive results from a late-stage trial of its experimental prostate cancer therapy.

The FDA's cancer advisors will discuss AstraZeneca’s application for the oral SERD camizestrant in breast cancer and the AKT ...